Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - ENZON PHARMACEUTICALS, INC. | Financial_Report.xls |
| EX-31.2 - EXHIBIT 31.2 - ENZON PHARMACEUTICALS, INC. | v409820_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ENZON PHARMACEUTICALS, INC. | v409820_ex31-1.htm |
| EX-32.1 - EXHIBIT 32.1 - ENZON PHARMACEUTICALS, INC. | v409820_ex32-1.htm |
| 10-Q - FORM 10-Q - ENZON PHARMACEUTICALS, INC. | v409820_10q.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Enzon Pharmaceuticals, Inc. (the Company) on Form 10-Q for the quarterly period ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Richard L. Feinstein, Vice President–Finance and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| May 13, 2015 | /s/ Richard L. Feinstein |
| Richard L. Feinstein | |
| Vice President–Finance and | |
| Principal Financial Officer | |
| (Principal Financial Officer) |
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Enzon Pharmaceuticals, Inc. and will be furnished to the Securities Exchange Commission or its staff upon request.